News | December 19, 2006

Siemens, UCLA to Study Alzheimer's Imaging Agent

Siemens Medical Solutions announced today that it will begin clinical trials on what could be a breakthrough imaging biomarker that the company hopes could identify Alzheimer’s disease prior to the onset of noticeable symptoms.

Siemens will collaborate with leading Alzheimer’s researchers at the University of California-Los Angeles to launch a Phase I, open label, single-center safety study of one of the first imaging biomarkers designed to identify Alzheimer’s disease pathology specifically. The study will employ a diagnostic technique developed by UCLA researchers that combines the new imaging biomarker and positron emission tomography.

The study protocol will focus on the use of the biomarker in patient populations and its potential to seek out tangles and plaques in the living brain of Alzheimer’s disease patients. Using PET imaging, biomarker molecules are considered to have the potential to “light up” the parts of the brain with high concentrations of the imaging biomarker; through analysis of the PET data, researchers can thus identify the disease specifically, and do so in advance of the onset of symptoms.

Related Content

News | Neuro Imaging | November 14, 2018
Artificial intelligence (AI) technology improves the ability of brain imaging to predict Alzheimer’s disease, according...
Proton Therapy for Pediatric Brain Tumors Has Favorable Cognitive Outcomes
News | Proton Therapy | November 06, 2018
Proton therapy treatment for pediatric brain tumor patients is associated with better neurocognitive outcomes compared...
150-Year-Old Drug Might Improve Radiation Therapy for Cancer
News | Radiation Therapy | November 02, 2018
November 2, 2018 — A drug first identified 150 years ago and used as a smooth-muscle relaxant might make tumors more
SBRT Considered Safe Treatment Option for Patients With Multiple Metastases
News | Stereotactic Body Radiation Therapy (SBRT) | November 01, 2018
The NRG Oncology clinical trial BR001 tested the hypothesis that stereotactic body radiotherapy (SBRT) could be used...
Hypofractionated Radiation Provides Same Prostate Cancer Outcomes as Conventional Radiation
News | Intensity Modulated Radiation Therapy (IMRT) | October 31, 2018
An analysis led by researchers at Philadelphia’s Fox Chase Cancer Center found treating localized prostate cancer with...
Prostate Brachytherapy Shows Low Incidence of Short-Term Complications
News | Brachytherapy Systems | October 31, 2018
A new analysis of nearly 600 men receiving brachytherapy for prostate cancer shows overall procedure-related...
Biomarker blood test accurately confirms remission in non-smoker with HPV-associated oral cancer. ASTRO 2018 #ASTRO2018 #ASTRO #ASTRO18

Biomarker blood test accurately confirms remission in non-smoker with HPV-associated oral cancer.

News | Radiation Oncology | October 30, 2018
October 30, 2018 — A highly sensitive blood test that detects minute traces of cancer-specific DNA has been shown to
Radiation/Cisplatin Established as Standard of Care for HPV-related Head and Neck Cancer. #ASTRO #ASTRO18 #ASTRO2018
News | Radiation Oncology | October 30, 2018
October 30, 2018 — Combinations of radiation and chemotherapy drugs have been shown to cure human papilloma virus (HP